WeightWatchers acquires **Sequence**, a telehealth provider specializing in weight-loss care. Sequence’s subscription model includes a **$99/month** app fee with access to clinician-led telehealth appointments. The company reports **$25 million in annual revenue** and serves **24,000 members** before the acquisition.
WeightWatchers expands into injectable weight management drugs as its next growth area. The company, known for digital tools like meal tracking and point systems, now targets clinical interventions to complement its existing offerings. This move aligns with rising demand for pharmaceutical-assisted weight loss solutions.
WW International, Inc. finalizes the acquisition of Sequence, expanding its portfolio of wellness brands. The deal consolidates Sequence’s offerings under WW’s broader health and wellness platform, targeting integrated solutions for weight management and lifestyle improvement.
WeightWatchers is acquiring **Sequence**, a digital health platform specializing in clinical weight management. The move combines WeightWatchers’ established nutrition and behavioral science programs with Sequence’s clinical-grade tools. Together, they aim to integrate personalized weight-loss solutions for healthcare providers and patients.
